Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia
2016 ◽
Vol 34
(15_suppl)
◽
pp. 7027-7027
2018 ◽
2018 ◽
2019 ◽
Vol 23
(12)
◽
pp. 4355-4363
◽
2012 ◽
Vol 97
(Suppl 2)
◽
pp. A122-A122